Background and Purpose-We aimed to describe the uptake of proven secondary prevention strategies for ischemic stroke in urban China. Methods-In a prospective, multicenter, hospital-based registry of 4782 cases of acute ischemic stroke in China during 2006, the use of secondary prevention regimens was evaluated before hospital discharge and 3 and 12 months after stroke. Logistic regression analysis was performed to determine associations between various baseline variables and in-hospital use of antihypertensive, antiplatelet, and lipid-lowering therapies, and to identify variables associated with their continuation at 12 months. Results-In-hospital initiation of antihypertensive (63%), antiplatelet (81%), and lipid-lowering (31%) therapies was influenced favorably by previous use and comorbid cardiovascular risk factors and unfavorably by stroke severity. Antihypertensive use was well-maintained during follow-up, whereas use of antiplatelet and lipid-lowering therapy decreased (66% and 17%, respectively; PϽ0.001) by 12 months after stroke, with discontinuation related to patient and physician factors. Interpretation-There was a high level of uptake of secondary prevention for ischemic stroke in this nationwide sample of hospitalized patients in urban China. However, use of antiplatelet and lipid-lowering therapy declined substantially after discharge, apparently related to misperceptions of subsequent disease risk by both doctors and patients. (Stroke. 2010;41:967-974.)
W
ith one-fifth of the world's population, 1 China experiences 40% of all stroke deaths in developing countries and has stroke listed as a leading cause of death and disability. 2 Programs to detect and manage cardiovascular risk factors therefore are critical to reducing stroke in China. Much of this burden relates to recurrent events that affect up to 1 in 3 patients, increase morbidity, and more than double the risk of death. 3, 4 Ischemic stroke, the predominant stroke subtype, has clearly defined modifiable risk factors that can be effectively managed through proven secondary prevention regimens. Previous studies of the uptake of secondary stroke prevention in China have been restricted in location, thus limiting the conclusions that can be drawn. [5] [6] [7] [8] [9] [10] [11] We aimed to describe the current practice of secondary prevention of ischemic stroke in China and to determine factors that influence standards of, and potential barriers to, the uptake of proven therapies.
Materials and Methods
ChinaQUEST (Quality Evaluation of Stroke Care and Treatment) is a multicenter, prospective, hospital registry study. Chinese hospitals are classified as level 1 (community hospitals with only the most basic facilities and very limited inpatient capacity), level 2 (hospitals with at least 100 inpatient beds providing acute medical care and preventative care services to populations of at least 100 000), and level 3 (major tertiary referral centers in provincial capitals and major cities). Of 70 level 2 and level 3 hospitals we identified and invited to participate across the country, 62 hospitals in 37 cities agreed and completed the study requirements, as described in detail elsewhere. 12 In brief, the study included consecutive patients (age Ն15 years) who were admitted to hospital with a recent (Ͻ1 month) acute stroke during a 5-month period in 2006. At each hospital, a trained neurologist was responsible for data collection, including maintenance of a screening log of all consecutive patients who presented to the hospital with a possible diagnosis of acute stroke. Patients were invited to undergo 4 assessments: at baseline (performed as soon as possible after notification), at the time of hospital discharge, and at 3 and 12 months after stroke onset. Baseline information on demographics, pathological diagnosis, and management were obtained by face-to-face interviews or extraction from medical records, whereas those pertaining to the use of specific medications at 3 and 12 months were obtained mainly by telephone interview (Ͼ80%).
To ensure data quality, the database allowed reference range checks to be performed automatically and queries were generated for the electronic case record forms. All sites were visited at least twice by study monitors to conduct source data verification on a random selection of 10% of recruited patients. Written informed consent was obtained from all patients or an appropriate family member (in situations in which the patient was disabled) to participate. The study was approved by the ethics committees of Peking University First Hospital (Beijing), Ruijin Hospital (Shanghai), Prince of Wales Hospital (Hong Kong), and The University of Sydney. Good clinical practice guidelines in accordance with the Declaration of Helsinki were used and the privacy of patients was strictly protected.
Statistical Analysis
Logistic regression analysis was performed to determine associations between variables of interest and in-hospital use of specific secondary prevention therapies, and to identify variables associated with their continuation at 12 months after stroke. Univariate analyses were first conducted, followed by multivariate modeling adjusting for age, gender, education level, hospital location (situated in a "rich" province or "northern" China), and significant variables (PϽ0.05). In all univariate and multivariate models, hospital was introduced as a random effect to account for any clustering at the hospital level. Plausible interactions between main effects were also checked for in the multivariate models. To assess the robustness of the study results, sensitivity analyses stratifying information source (proxy vs patient) and mode of data collection (telephone vs in-person interview, when source was the patient) were conducted in the models of 12-month continuation. The 2 tests were performed to determine the significance of differences in the uptake of secondary prevention therapies between baseline (in hospital) and 3 and 12 months after stroke and in the reasons for discontinuation at 12 months after stroke by initial stroke severity.
Variables considered covered sociodemographics (age, gender, living alone, low education [primary education only or illiterate], marital status, current employment, and annual household income), medical history (history of hypertension, diabetes, hyperlipidemia, atrial fibrillation, stroke, TIA, coronary artery disease [includes any history of heart attack/myocardial infarction, angina or coronary heart disease]), and lifestyle (regular alcohol consumption, cigarette smoking, and being overweight [body mass index Ն24] 13,14 ). Hospital factors, including level, size, teaching status, and location of the hospital, were also investigated. The location of hospitals was either in a "rich" or "poor" provincial area classified according to whether the 2006 gross regional product per capita for the province was above or below the national average (2006 gross domestic product per capita 16 084 Chinese Yuan Renminbi 15 [United States $2298, based on an exchange rate of United States $1 being equivalent to 7 Chinese Yuan Renminbi, which is used throughout]). Hospitals situated in the areas of Beijing, Hebei, Heilongjiang, Henan, Inner Mongolia, Jilin, Liaoning, Qinghai, Shaanxi, Shandong, Tianjing, and Xinjiang were classified as "northern", whereas those located in the areas of Anhui, Chongqing, Fujian, Guangdong, Guangxi, Hong Kong, Hubei, Hunan, Jiangsu, Jiangxi, Shanghai, Sichuan, and Yunnan were classified as "southern". Other variables examined included severe disease (defined by Glasgow Coma Scale score Յ8) at presentation and disability/dependency (defined by scores 3-5 on the modified Rankin Scale) at discharge. Medical history was used in models of in-hospital medication use, whereas history plus new in-hospital diagnoses of hypertension, diabetes, hyperlipidemia, atrial fibrillation, and coronary heart disease were used in models of therapy continuation at 12 months after stroke. For the 12 months after stroke analyses, history of hyperlipidemia also included patients with a total cholesterol level Ͼ5.72 mmol/L (220 mg/dL; the threshold level for treatment recommended in the national Chinese 13 ‡Includes 616 (20%) cases diagnosed after stroke in hospital but excludes 229 patients with discharge blood pressure Ն140/90 mm Hg.
§Includes 265 (26%) cases diagnosed after stroke in hospital. ¶Includes 968 (56%) cases diagnosed after stroke in hospital.
Includes 91 (30%) cases diagnosed after stroke in hospital. **Includes 314 (34%) cases diagnosed after stroke in hospital. † †Within the 3 months before stroke onset. ‡ ‡Defined as Glasgow Coma Scale score of Յ8 on admission; percentage based on non-missing values.
§ §Defined as modified Rankin Scale scale score of 3 to 5 on discharge; percentage based on non-missing values. stroke guidelines 13 ) before hospital discharge. All data analyses were conducted using STATA 10.1 (StataCorp).
ChinaQUEST is an academic-initiated and academic-conducted study. The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Results
Of 13 038 patients screened for eligibility, 6530 (50%) were excluded because the final diagnosis was not stroke or stroke of recent onset (30.9%), patients refused to participate (16.1%), patient died rapidly before enrollment (1.5%), or other reasons (1.5%). A total of 6508 patients were enrolled but 154 were excluded because of uncertainty of diagnosis and missing data, resulting in 6354 cases, of which 4782 (75%) were attributable to ischemic stroke. Within this latter subset, there were 491 deaths and 158 cases with incomplete data, leaving 4133 12-month survivors with complete baseline and follow-up information for analyses. Table 1 shows the baseline demographic and clinical profile of patients were typically high for cardiovascular risk factors, most notably for hypertension and being overweight. On admission to hospital, 72%, 85%, and 25% of patients with known hypertension, diabetes, and hyperlipidemia were using treatment, respectively; half of those with atrial fibrillation received antithrombotic treatment (5% warfarin, 44% aspirin). Tables 2, 3 , and 4 present the associations of key baseline variables with in-hospital use and continuation of secondary prevention therapies at 12 months after stroke. No significant interaction effects in the variables were detected and sensitivity analyses showed no significant differences when stratifying by information source (patient vs proxy) or mode of data collection (face-to-face vs telephone interview).
Briefly, multivariate analyses showed that patients with a severe stroke were significantly less likely to receive each of the secondary prevention regimens, and having a history of cardiovascular disease generally resulted in increased likelihood of antihypertensive and lipid-lowering therapy in hospital. With regard to continuation of therapy in survivors who had received the therapy in hospital, those with history of comorbid conditions were more likely to continue, whereas current smokers and regular drinkers were less likely to continue antiplatelet and antihypertensive therapy, respectively. The use of secondary prevention therapies during follow-up is shown in Figure 1 . Antihypertensive use was well-maintained across the 3 time points but use of antiplatelet and lipid-lowering therapies declined at 3 and 12 months after stroke. Corresponding figures for antihypertensive use in "hypertensive" patients were 73%, 76%, and 73%, and were 56%, 35%, and 27% for "hyperlipidemic" patients. The main reasons for discontinuation of the various regimens were that either the patient did not have a condition diagnosed as requiring or indicating therapy or the patient refused to use the medication or failed to refill the prescription (Figure 2 ).
Reasons for discontinuation did not differ significantly by initial stroke severity.
Discussion
This large, prospective, national, multicenter study provides an overview of the current practice of secondary prevention for ischemic stroke in urban China. Notably, usage of secondary prevention therapies during the initial hospital management of patients was influenced favorably by concurrent indication(s) for treatments and the presence of comorbid cardiovascular disease. Use of such therapies was also influ- enced by stroke severity; patients with severe disease were less likely to receive such treatment, possibly because of receiving more conservative management. Importantly, this study also highlights marked declines in the use of antiplatelet and lipid-lowering therapies over the year after the discharge of patients from hospital. These trends were attributed in part to both physician and patient misperceptions of prescribing need. Sociodemographic factors were generally not related to in-hospital use of secondary prevention therapies, with a few notable exceptions. Consistent with results from a large-scale study in Scotland, females were less likely to continue antiplatelet therapy by 12 months after stroke. 16 However, our study also indicated that lipid-lowering therapy was used more often in females, which was unexpectedly contrary to findings in Western populations. 16, 17 The disparity may be because of differences in culture and health care systems between China and other countries, but it may also be attributable to ethnic variations in distributions of comorbidities between women and men in China and in the West. Interestingly, our results also suggest continuation of lipidlowering therapy improves with increasing age, a phenomenon that could be attributable to increasing comorbidities with age and also potentially increased wealth, such that expensive lipid-lowering therapy would be more affordable. We also found that patients with a history of atrial fibrillation were less likely to receive lipid-lowering therapy and that there was some evidence to suggest that patients with higher incomes were more likely to continue lipid-lowering therapy, possibly reflecting uncertainty about the benefits, potential risks, 18 and high costs of statins in China.
We have shown that use of antihypertensive agents was relatively well-maintained, but the use of antiplatelet and lipid-lowering therapies declined over the course of 12 months after stroke. Our finding of moderate (73%) use of antiplatelet therapy at 3 months after stroke is consistent with results from small-scale studies undertaken in China in recent years. 5, 6, 8 Whereas comparable data on the long-term uptake of secondary prevention therapies remain scarce outside of China, use of antihypertensives, antiplatelet, and lipidlowering treatment in patients with ischemic stroke was documented to be as high as 90%, 93%, and 70%, respectively, at 1 year after stroke in Germany. 19, 20 In addition, Lummis et al 21 reported that the use of antihypertensives, antiplatelets, and antilipidemic agents was 88%, 80%, and 75%, respectively, at 12 months after discharge after an ischemic stroke in Canada. The large discrepancies in use of lipid-lowering therapy between China and other countries is notable but could be attributable to the higher prevalence of ischemic heart disease and hyperlipidemia in Western populations.
We have shown that a combination of patient and physician factors influence adherence to secondary prevention regimens after stroke. Discontinuation of aspirin was noted to be particularly high, with 71% of patients refusing or not refilling the prescription for the medication. Such discontinuation may be attributed to lack of awareness of the importance of such treatment, as in other areas of medicine when the beneficial (and adverse) effects of agents may not manifest symptomatically. Thus, patients with poor motivation and misconceptions have difficulty continuing treatment, as highlighted in another study 11 of ischemic stroke patients in China, where patients regarded aspirin as "rheumatoid arthritis treatment" and believed that they would not benefit from using it. Consequently, education and support may improve the situation, particularly given that social support in terms of marriage was significantly correlated with reduced discontinuation of lipid-lowering therapy. Interestingly, few of the patients in our study reported financial difficulty as a major reason for cessation of medication. This may have been because of bias in reporting, denial, or the inclusion of many insured people who could afford hospital care and subsequent medications.
Our study also emphasizes that clinicians may contribute to the problem of discontinuation, with 12% of them not considering antiplatelet therapy necessary in their patients with ischemic stroke despite national (Chinese) guideline recommendations for general use in this patient group. 13 Figure 1 . Percentage of patients with ischemic stroke using different secondary prevention regimens in hospital and at 3 and 12 months after stroke (*PϽ0.001). Proportions represent overall use at each point in time. A further 34, 42, 36 patients received anticoagulation with warfarin in hospital, at 3 months, and at 12 months, bringing total antithrombotic use to 82%, 74%, and 67%, respectively.
However, these guidelines also advocate for antihypertensive and lipid-lowering treatment only in ischemic stroke patients with "hypertension" and "hyperlipidemia," respectively, whereas international guidelines, such as those of the latest American Heart Association/American Stroke Association, recommend the use of such treatments in all ischemic stroke patients. 13, 22, 23 Nonetheless, the 40% level of discontinuation of antihypertensives in hypertensive patients and 60% discontinuation of lipid-lowering therapy in hyperlipidemic patients were still attributed to either lack of diagnosis or indication for such therapy. Therefore, in addition to improved patient education programs and physician awareness, the Chinese guidelines may require updating in terms of their recommendations regarding the secondary prevention of stroke.
This study has several limitations that deserve comment. First, the selected network of level 2 and level 3 hospitals in major cities may have included patients with higher levels of education, income, and help-seeking behavior and who received higher standards of care than patients in other hospitals and locations in China. Given the enormity of the population and vast number of hospitals (Ϸ20 000 in 2006), we did not have resources to extend the study into rural areas and level 1 hospitals. Nevertheless, given the large and extensive geographic coverage of the study and the heavy reliance on hospitals for chronic health care delivery, we believe that our study provides a useful representative picture of the current state of secondary prevention of ischemic stroke in urban China. Any effect of selection and participation biases is likely to have been toward underestimation of the true evidence-practice gap. Second, our measures of risk exposures and medication usage were either based on selfreport or extracted from medical records, raising issues of recall and information biases. However, sensitivity analyses revealed no significant differences between patient and proxy sources of information, or between face-to-face and telephone modes of data collection. Moreover, both self-reported medical history and medication use have been shown to correlate well with medical and pharmacy records, respectively, and the reliability of such data are still high via proxy respondents and telephone-based methods of data collection. 24 -27 Finally, consistency of the findings with other studies of more limited scope in China provides further reassurance of the validity of our data.
Conclusions
In summary, this study documents the current state of secondary prevention of ischemic stroke among a large nationwide sample of patients in urban China. The feedback provided may assist in implementing activities, including the design and evaluations of interventions, to improve the uptake of secondary prevention strategies and efforts to reduce the burden of stroke in this huge country undergoing rapid epidemiological and economic transition. scientific, data management, and statistical staff associated with the study. The authors also thank Professor Kjell Asplund for his appraisal of and commentaries on the manuscript.
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Figure 2.
Reasons for discontinuation of secondary prevention therapies at 12 months after stroke. Sectors contributing Յ1% to the pie chart are not labeled but are included for completeness. Aspirin was used to represent all antiplatelet agents because patients were asked to evaluate reasons for discontinuation of aspirin, aspirin/dipyridamole, and clopidogrel, separately, although the majority (97%) of patients used aspirin. Discontinuation of aspirin use is evaluated only in patients without atrial fibrillation.
